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1. Introduction {#sec001}
===============

The human body and, in particular, the gastrointestinal tract (GIT) hosts a variety of microbial populations referred to collectively as the microbiome \[[@pone.0228531.ref001]\]. The microbiome of the GIT plays a key role in the maintenance of a healthy immune system \[[@pone.0228531.ref001], [@pone.0228531.ref002]\], and disruptions to the microbiome composition can lead to serious effects on health \[[@pone.0228531.ref003]--[@pone.0228531.ref005]\]. In order to maintain a healthy microbiome, regular ingestion of probiotic supplements, or the ingestion of fermented dairy products/capsules has been suggested. These practices have led to various improved health outcomes, ranging from enhanced overall human wellbeing to the treatment of infections, constipation, diarrhoea etc \[[@pone.0228531.ref001]\].

The majority of probiotics belong to the lactic acid bacteria (LAB) family; gram positive lactic acid producing microorganisms that include several genera such as bifidobacteria, lactobacilli streptococci and enterococci \[[@pone.0228531.ref001]\]. The small intestine and the colon are highly enriched with these microorganisms \[[@pone.0228531.ref006]--[@pone.0228531.ref008]\], which are routinely supplemented in foods as live strains due to their beneficial effects on human health \[[@pone.0228531.ref001], [@pone.0228531.ref002], [@pone.0228531.ref008]--[@pone.0228531.ref013]\]. *Streptococcus* species such as exopolysaccharide-producing strains of *Streptococcus thermophilus* (ST) \[[@pone.0228531.ref012], [@pone.0228531.ref014], [@pone.0228531.ref015]\] are among those consumed. These characteristics of *S*. *thermophiles* enable them to be used in fermented milk products (i.e. yogurt) including flavoring of dairy, and is recognized as the next most important species after *Lactococcus lactis* \[[@pone.0228531.ref016], [@pone.0228531.ref017]\]. ST and *L*. *brevis* synergistically display well established health benefits, and *S*. *thermophilus* is one of the bacteria in the VSL\#3 probiotic mixture, which has long been broadly applied in the treatment of inflammatory conditions \[[@pone.0228531.ref018], [@pone.0228531.ref019]\]. In addition, probiotics interact with the immune system leading to immunomodulation and anti-inflammatory properties \[[@pone.0228531.ref004], [@pone.0228531.ref020], [@pone.0228531.ref021]\].

The 'hygiene hypothesis' suggests that the positive trend in the incidence of immune-related disorders can been attributed to intestinal dysbiosis, resulting in immune dysfunction (ie. asthma, eczema, allergies and autoimmune diseases). Use of probiotic bacteria can increase abundance and concurrently modulate immune cells, including B, T helper (Th)-1, Th-2, Th-17 and regulatory T (Treg) cells. This in turn, directly influences human health and modulates pathologies of immune/autoimmune diseases \[[@pone.0228531.ref001], [@pone.0228531.ref002], [@pone.0228531.ref013]\]. In fact, we previously noted that *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 and *S*. *thermophilus* 285 modulate the U937 monocyte cell line. Specifically, we showed that interleukin (IL)-4, IL-10, GM-CSF and CXCL8 production were increased, and, cell surface marker expression CD11c, CD86, C206, CD209, MHC-1 were upregulated \[[@pone.0228531.ref001]\]. In another study, *S*. *thermophilus* 1275 and *Bifidobacterium longum* BL536 demonstrated increased levels of transforming growth factor (TGF)-beta (a key factor in the differentiation of Treg and T-helper Th)-17 cells by bulk peripheral blood mononuclear cell (PBMC) cultures \[[@pone.0228531.ref022]\]. Primary macrophages co-cultured with ST bacteria stimulate production of anti-inflammatory IL-10 and pro-inflammatory IL-12 cytokines \[[@pone.0228531.ref023]\].

Peripheral blood mononuclear cells (PBMC) isolated from whole blood constitute a wide range of diverse immune cells that play vital roles in balancing immune homeostasis and keeping human health in check \[[@pone.0228531.ref024], [@pone.0228531.ref025]\]. These cells are crucial components of the innate and adaptive immune system, defend the body against bacterial, viral and parasitic infections, as well as destroying foreign antigens and cancer cells \[[@pone.0228531.ref025]\]. PBMC are predominantly made up of lymphocytes (\~70--90%), monocytes (\~10--20%) and other cells such as dendritic cells comprise less than 1--2% \[[@pone.0228531.ref026]\]. In spite of variations in the fraction of subtypes of immune cells within the total PBMC isolated from different samples \[[@pone.0228531.ref026]\], isolation, characterization and molecular studies of these cells have benefited medical research \[[@pone.0228531.ref027]\].

Herein, we describe changes in the expression of genes associated with innate and adaptive immunity including cytokines, chemokines and immune cell marker expression by human PBMC following exposure to live *S*. *thermophilus* 285 bacteria.

2. Material and methods {#sec002}
=======================

2.1. Bacterial strains {#sec003}
----------------------

Pure bacterial cultures of *S*. *thermophilus* 285 were obtained from Victoria University culture collection (Werribee, VIC, Australia). Stock cultures were stored in cryobeads at −80°C. Prior to each experiment the cultures were propagated in M17 broth (Oxoid, Denmark) with 20 g/L lactose and incubated at 37°C under aerobic conditions. Bacteria were also cultured in M17 agar (1.5% w/v agar) with 20 g/L lactose (Oxoid, Denmark), to assess characteristics, morphology, purity and gram-positive confirmation \[[@pone.0228531.ref001]\].

2.2. Preparation of live bacterial suspensions {#sec004}
----------------------------------------------

Media were prepared and autoclaved at 121°C for 15 minutes (mins) prior to experiments. Bacterial cultures were grown 3 times in M17 broth with 20 g/L lactose, at 37°C aerobically for 18 hours (hr) with a 1% inoculum transfer rate \[[@pone.0228531.ref028]\]. Cultures grow optimally at 37--42°C for 24 hrs \[[@pone.0228531.ref015]\]. The growth period of cultures were consistent at 18 hr (at the end of the exponential growth phase) and before stationary growth phase to prevent cell lysis. Bacteria were harvested during stationary growth phase on the day of experiment, centrifuged (6000×g) for 15 min at 4°C, followed by two washes with Dulbecco's phosphate-buffered saline (DPBS) (Invitrogen, Pty Ltd. Australia) and resuspended in the Roswell Park Memorial Institute (RPMI) 1640 culture media. These samples constituted the live-cell suspensions.

2.3. Enumeration of bacterial cells {#sec005}
-----------------------------------

Bacterial strains were scraped from M17 agar and transferred into Dulbecco's PBS (Invitrogen, Pty Ltd. Australia) adjusted to a final concentration of 10^8^ colony forming units (cfu)/ml by measuring the optical density at 600 nm, and washed two times with PBS and resuspended in RPMI 1640 prior to co-culturing with PBMC \[[@pone.0228531.ref001]\].

2.4. Isolation, culture, and stimulation of PBMC {#sec006}
------------------------------------------------

### 2.4.1. Isolation of PBMC using Ficoll-Paque {#sec007}

PBMC isolation from whole blood was via Ficoll-Paque density gradient centrifugation \[[@pone.0228531.ref009]\]. Three buffy coats were collected from the Australian Red Cross Blood Bank on the day of experiment (Victoria University human research ethics). Calcium and magnesium free PBS, pH7.2, (Invitrogen, Pty Ltd. Australia) was used after adding 2 mM EDTA and 2% heat-inactivated fetal bovine serum (FBS) (Invitrogen, Pty Ltd. Australia); PBS buffer. SEPMATE tubes (50 ml) with inner inserts (STEMCELL technology, Canada) were used to isolate PBMC following Ficoll-Paque density gradient protocol \[[@pone.0228531.ref029], [@pone.0228531.ref030]\]. PBMCs were washed, counted and the required number of PBMC were co-cultured with *S*. *thermophilus* 285 and the remaining PBMC were stored in freeze mix and transferred into liquid nitrogen for future use.

### 2.4.2. Stimulation of PBMC with *S*. *thermophilus* 285 {#sec008}

PBMC (3x 10^7^ cells) were resuspended in RPMI 1640 media supplemented with 10% heat-inactivated FBS (Invitrogen, Pty Ltd. Australia), 1% antibiotic-antimycotic solution and 2 mM L-glutamine in cell culture flasks, and 3x10^8^ *S*. *thermophilus* 285 bacteria were added. PBMC with RPMI media without the addition of ST285 bacteria were used as a control and incubated at 37°C, 5% CO~2~ for 24 hrs \[[@pone.0228531.ref001]\]. We previously demonstrated that 24 hrs co-culture was optimal for stimulation of U937 monocyte/macrophage cell line, and all incubations described herein were for 24 hrs \[[@pone.0228531.ref001]\]. PBMCs were snap frozen post incubation and stored at -80°C prior to RNA extraction.

2.5. RNA extraction from PBMC {#sec009}
-----------------------------

Total RNA was extracted from stimulated PBMCs using the RNeasy^®^ mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Briefly, cells were centrifuged and harvested, supernatants were removed and RNA extracted from each cell pellet and resuspended in lysis buffer supplemented with β-mercaptoethanol to disrupt the cells. PBMC were lysed and each cell lysate passed through the supplied Qia-shredder columns to homogenize and was subsequently mixed with equal volume of 70% ethanol. Cell lysates were transferred onto RNeasy mini-spin columns and DNA was removed using DNase digestion/ treatment using RNase-Free DNase Set (Qiagen, Hilden, Germany.) The RNA Integrity Number (RIN) of all RNA samples were measured using an Agilent 2100 Bioanalyzer and Agilent RNA 6000 nano kit (Agilent Technologies, Santa Clara, CA, USA); with a minimum RIN of 7.5 used as the criterion for inclusion in gene expression analysis. The concentration of each individual RNA sample was measured using a Qubit RNA BR Assay (Invitrogen) in triplicate. Several blood samples were collected for PBMC isolation, treatment and extraction of RNA and only RNA samples with the highest RIN numbers (all above 8) were included for PCR.

2.6. Assessing changes in the expression of genes associated with innate and adaptive immunity {#sec010}
----------------------------------------------------------------------------------------------

Aliquots of each RNA sample were reverse-transcribed to make complementary DNA (cDNA) using RT^2^ first strand kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the 'Human Innate and Adaptive immune Response' kit (Qiagen, Hilden, Germany) to evaluate gene/mRNA expression. The relative expression profiles of treated PBMC samples were analyzed in comparison with untreated PBMC cultured in RPMI using Thermo-cycler (Biorad, Melbourne Australia). The RT^2^ qPCR Primer innate and adaptive immune response arrays target a set of 84 innate and adaptive immune-related genes and five housekeeping genes, an RT control, a positive PCR control, and a human genomic DNA contamination control. The levels of the expression of these genes were calculated using the Qiagen web-based software (Qiagen, Germany) and then calculated the fold changes and analyzed data manually to compare results. Differential expression (up and down regulation) of the genes were identified using the criteria of a \> 2.0-fold increase/decrease in gene expression in treated PBMCs in comparison with those genes in control PBMC cultures.

2.7. Data analysis {#sec011}
------------------

The Delta-Delta CT (ΔΔCT) was used to calculate fold-changes \[[@pone.0228531.ref031]\]. Fold-regulation represents fold-change results in a biologically meaningful way. In our RT2 profiler PCR array results, fold-change values greater than one, indicate a positive (or an up-) regulation, in fact in upregulated genes, the fold-regulation is equal to the fold-change. Fold-change values less than one specifies a negative (or a down) regulation, and in this case, the fold-regulation is the negative inverse of the fold-change \[[@pone.0228531.ref032]--[@pone.0228531.ref034]\]. Data related to changes in the expression of the genes were analyzed by ΔΔCT method using Qiagen RT^2^ profiler data analysis webportal that utilises the delta delta CT method in determining fold-changes. The raw CT values were uploaded to the Qiagen data analysis webportal with the lower limit of detection set for 35 cycles and 3 internal controls: PCR array reproducibility, RT efficiency and genomic DNA contamination were assessed to ensure all arrays successfully passed all of these control checks. Normalization of the raw data was performed using the included housekeeping genes (HKG) panel. Then using the ΔΔCT method, both housekeeping gene references and untreated/ controls were assessed to calculate relative expression of mRNA.

2.8. Statistical analysis {#sec012}
-------------------------

The p values are calculated based on a Student's *t-test* of the Triplicate 2\^ (- Delta CT) \[(2\^-ΔCT)\] values for each gene in the treatment group vs. the control group \[[@pone.0228531.ref032], [@pone.0228531.ref033], [@pone.0228531.ref035], [@pone.0228531.ref036]\].

3. Results {#sec013}
==========

Among 84 genes assessed, 31 genes were significantly altered \> 2.0 fold up/down in PBMC samples (n = 3) following exposure to *S*. *thermophilus* 285 compared to control PBMC ([Fig 1](#pone.0228531.g001){ref-type="fig"}, Table in [S1 Table](#pone.0228531.s001){ref-type="supplementary-material"} and [S1 Fig](#pone.0228531.s002){ref-type="supplementary-material"}).

![Effects of co-culturing *S*. *thermophilus* 285 with PBMCs (n = 3) on gene/RNA expression compared to control PBMCs after 24 hrs.\
(A) All 84 genes are shown including those with significant high up/down regulated genes (more than 2-fold) and those with no significant change (less than 2-fold). The housekeeping genes (HKG) panel and other genes used for normalization of the raw data are not presented. Letter A specifies the gene's average threshold cycle to be reasonably high (\> 30) in either the treated samples or the controls and relatively low (\< 30) in the other/opposite sample. Thus, in case of presenting fold changes with letter A, the estimate fold change may be an underestimate. Letter B suggests a reasonably high (\> 30) gene's average threshold cycle that means a low level of average expression of relevant gene, in both test/treated samples and untreated control samples, and the p-value for the fold-change might be either relatively high (p \> 0.05). Thus, in case of presenting fold changes with letter B, the estimate fold change may be slightly overestimate or unavailable. Letter C indicates that that gene's average threshold cycle is either not determined or greater than the defined default 35 cut-off value, in both test/treated samples and control samples, suggesting that its expression was not detectable, resulting in the fold-change values being un-interpretable \[[@pone.0228531.ref086], [@pone.0228531.ref087]\] \[[@pone.0228531.ref088]\]. (B) Presentation of data as a hierarchical clusters of average gene/RNA expressions of PBMC (n = 3) co-cultured with *S*. *thermophilus* 285, compared to control. Green represents down regulated genes to red represents upregulated genes.](pone.0228531.g001){#pone.0228531.g001}

3.1. *S*. *thermophilus* 285 alters cytokine gene expression levels of PBMC {#sec014}
---------------------------------------------------------------------------

### 3.1.1. Interleukin mRNA expression levels {#sec015}

IL-1α and IL-6 are secreted by dendritic cells (DC), B cells and macrophages (MQ) are involved in acute phase responses, B cell maturation, macrophage differentiation, promote Th2 differentiation and inhibit Th1 polarization. IL-1α is upregulated 2.78 ± 0.6 fold and IL-6 25.12 ± 0.61 fold ([Fig 2](#pone.0228531.g002){ref-type="fig"}). IL- 23α is secreted by CD4^+^ T cells and aids in the stimulation of Th17 cells together with IL-6. IL-23α is highly upregulated 3.8 ± 1.0 fold ([Fig 2](#pone.0228531.g002){ref-type="fig"}). IL-2 has an array of functions it activates T cell proliferation and increases or decreases inflammatory responses. IL-2 is downregulated 7.27 ± 0.53 fold ([Fig 2](#pone.0228531.g002){ref-type="fig"}). IL-17A a pro-inflammatory cytokine secreted by Th17 cells, was not altered following PBMC co-cultured with *S*. *thermophilus* 285.

![(A) IL-1α, IL-23α and IL-2 and (B) IL-6, mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \*\* *p* \< 0.04.](pone.0228531.g002){#pone.0228531.g002}

### 3.1.2. Th1/Th2 mRNA expression levels {#sec016}

IFNγ, a Th1 cytokine important in the defense against bacterial infection is upregulated 8.73 ± 0.94 fold. Likewise, the Th1 cytokine IL-1β is upregulated 4.82 ± 0.74 fold ([Fig 3](#pone.0228531.g003){ref-type="fig"}). Of interest, IL-18 a Th1 inducing pro-inflammatory cytokine was vastly downregulated (75 ± 0.66 fold), in addition, IFNγR1, a transmembrane protein which interacts with IFNγ, is also downregulated 4.03 ± 0.25 fold ([Fig 3](#pone.0228531.g003){ref-type="fig"}). Tumor-necrosis factor-alpha (TNFα), important in the defense against bacterial infections, and in acute phase reactions is upregulated 6.10 ± 1.4 fold ([Fig 3](#pone.0228531.g003){ref-type="fig"}). IL-10, an anti-inflammatory cytokine secreted by Th2 and Treg cells is upregulated 2.05 ± 0.52 fold ([Fig 3](#pone.0228531.g003){ref-type="fig"}). Gene expressions of other cytokines, IFNB1, IL-4, IL-5 and IL-13 are not significantly altered.

![A) TNF-α, IL-10, IL-1β, IFN-γ, and IFN- γ--R and (B) IL-18, mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
(The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \* *p* \< 0.05, \*\* *p* \< 0.04, \*\*\* *p* \< 0.02 and \*\*\*\* p \< 0.01.](pone.0228531.g003){#pone.0228531.g003}

3.2. *S*. *thermophilus* 285 alters chemokine gene expression levels of PBMC {#sec017}
----------------------------------------------------------------------------

Chemokine (CXCL8, IL-8) is important in the innate immune system, it stimulates chemotaxis and is upregulated 11.26 ± 0.27 fold following *S*. *thermophilus* 285 co-culture with PBMC cells. However, CCR5 and CXCL10 (INP10) are down regulated 6.29 ± 0.32 and 5.30 ±1.8 fold respectively ([Fig 4](#pone.0228531.g004){ref-type="fig"}). No significant differences are noted for gene expressions of other chemokines, including CCL2 (MCP-1), CCL5 (RANTES), CCL8, CCR4, CCR8, CXCR3, CCL2, IFNA1.

![CCR5, CXCL10 and CXCL8 (IL-8), mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \*\* *p* \< 0.04.](pone.0228531.g004){#pone.0228531.g004}

3.3. Colony stimulating factor mRNA expression levels {#sec018}
-----------------------------------------------------

Colony-stimulating factor (CSF)-2, secreted by MQs, NK cells and T cells, enables cell proliferation and differentiation and is significantly increased by 130.35 ± 1.0 fold ([Fig 5](#pone.0228531.g005){ref-type="fig"}) after co-culturing PBMC with *S*. *thermophilus* 285 bacteria.

![CSF-2, mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \*\*\*\* p \< 0.01.](pone.0228531.g005){#pone.0228531.g005}

3.4. *S*. *thermophilus* 285 alters Toll like receptor gene expression levels of PBMC {#sec019}
-------------------------------------------------------------------------------------

TLR (toll like receptor)-1, TLR-2, TLR-4 and TLR-8 are part of the innate immune response and involved in the defense response to bacteria. PBMC co-cultured with *S*. *thermophilus* 285 induced downregulation of TLRs at varying levels; TLR-1 (-2.63 ± 0.43), TLR-2 (-2.69 ± 0.8 fold), TLR-4 (-5.65 ± 0.56 fold), TLR-8 (-11.41 ± 1.27 fold) ([Fig 6](#pone.0228531.g006){ref-type="fig"}). However, changes to other pattern recognition receptors such as, TLR-3, TLR-5, TLR-6, TLR-9 were not significant.

![TLR-1, TLR-2, TLR-4 and TLR-8, mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \* *p* \< 0.05, \*\* *p* \< 0.04 and \*\*\* *p* \< 0.02.](pone.0228531.g006){#pone.0228531.g006}

3.5. Cell surface markers CD14, CD40, CD86 mRNA expression levels {#sec020}
-----------------------------------------------------------------

Expression of the monocyte cell surface markers CD14, CD40 and CD86 significantly downregulated -25.29 ± 3.46, -15.39 ± 1.36, -8.04 ± 0.14 fold, respectively ([Fig 7](#pone.0228531.g007){ref-type="fig"}). Expression of the CD8A gene, which is involved in adaptive immunity and in response to defense against viruses, was downregulated by -2.96 ± 0.68 fold ([Fig 7](#pone.0228531.g007){ref-type="fig"}). Expression of CD4, CD80, FOXP3, STAT3, CD40LG (TNFSF5), HLA-A, HLA-E and RORC genes do not show significant changes.

![(A) CD40 and (B) CD14, CD86 and CD8A, mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \* *p* \< 0.05, \*\* *p* \< 0.04 and \*\*\* *p* \< 0.02.](pone.0228531.g007){#pone.0228531.g007}

3.6. Changes to other innate and adaptive molecules, mRNA expression levels {#sec021}
---------------------------------------------------------------------------

Changes to other genes were also noted following *S*. *thermophilus* 285 co-culture with PBMC. ACTB (-3.01 ± 1.0) fold, ITGAM (-2.76 ± 0.9) were both downregulated. Downregulated genes were noted to the following: MPO (2.33 ± 0.2), NLRP3 (2.11 ± 0.6), SLC11A1 (4.72 ± 0.23) and complement component (C)-3 (3.38 ± 1.5), TYK2 (10.03 ± 0.7), IRF7 (12.32 ± 0.4), LYZ (37.91 ± 0.4) and GATA3 (22.15 ± 1.64) ([Fig 8](#pone.0228531.g008){ref-type="fig"}). Other immune markers including FASLG (TNFSF6), CRP, IFNAR1, JAK2, IL-1R1, MAPK8 (JNK1), IRF3, MBL2, NFKB1, MX1, ICAM1, MBL2, MYD88, NOD1 (CARD4), NOD2, DDX58 (RIG-I), RAG1 and TICAM1 (TRIF) showed no significant mRNA gene changes in the levels of their expression.

![(A) ACTB, CCR5, ITGAM, MPO, NLRP3, SLC11A1, and C3 and (B) TYK2, IRF7, LYZ and GATA3, mRNA fold change following 24 h co-culture of *S*. *thermophilus* 285 with PBMCs (n = 3), compared to control PBMC.\
The innate and adaptive RT^2^ gene profiler arrays were used to determine changes in gene expression. Symbols represent *p* value for Tukey Test (One way ANOVA) where \* *p* \< 0.05, \*\* *p* \< 0.04 and \*\*\* *p* \< 0.02.](pone.0228531.g008){#pone.0228531.g008}

4. Discussion {#sec022}
=============

Our previous publications illustrated immune modulatory effects of *S*. *thermophilus* 285, *S*. *thermophilus* 1275 and *S*. *thermophilus* 1342 on U937 monocytic cell line and human monocytes by using secreted cytokines for bioplex assays, as well as flow cytometry of immune cell surface marker changes. The current study, aimed to get a more comprehensive overview of the data, by undertaking an in depth gene array analysis of the effects of probiotics to human PBMC.

4.1. *S*. *thermophilus* 285 promotes Th2 polarization {#sec023}
------------------------------------------------------

IL-1α secreted by peripheral blood DC and B cells induces Th2 differentiation and inhibits Th1 polarization \[[@pone.0228531.ref037]\], is significantly upregulated. Similarly, *Enterococcus faecium* NCIMB 10415 was shown to upregulate IL-1α in porcine jejunal epithelial cells (IPEC-J2) *in vitro*, \[[@pone.0228531.ref038]\]. IL-6 produced by Th2 cells is increased in the presence of *S*. *thermophilus* 285 by PBMC which was also shown previously to be upregulated by pro-monocyte cell line U937 \[[@pone.0228531.ref001]\]. Others have shown that PBMC co-cultured with *S*. *thermophilus* 1275 also increases IL-6 \[[@pone.0228531.ref039]\]. Likewise, mixed probiotics of *S*. *thermophilus*, *Lactobacillus* (*L*.) *rhamnosus*, *L*. *casei*, *L*. *acidophilus*, *B*. *longum* and *B*. *bifidum* stimulated PBMC to produce IL-6 \[[@pone.0228531.ref040], [@pone.0228531.ref041]\]. Our study shows that IL-1α and IL-6 are increased, highlighting the role of *S*. *thermophilus* 285 in stimulation of immune responses involved in acute phase; B cell maturation, macrophage differentiation, promotion of Th2 differentiation and inhibiting Th1 polarization.

IL-10 is an anti-inflammatory cytokine secreted by Th2 and Treg cells and co-culture of *S*. *thermophilus* 285 with PBMC increased expression of IL-10. Cultured PBMC with other live *S*. *thermophilus* strain (*S*. *thermophilus* 1275) also showed increased IL-10 \[[@pone.0228531.ref022], [@pone.0228531.ref039], [@pone.0228531.ref042]--[@pone.0228531.ref045]\]. Similarly, in a study using mixed probiotic cultures (*S*. *thermophilus*, *L*. *rhamnosus*, *L*. *casei*, *L*. *acidophilus*, *B*. *longum* and B. *bifidum*) high levels of IL-10 were stimulated by PBMC \[[@pone.0228531.ref040]\]. Conversely, in a study using *B*. *breve* and *S*. *thermophilus* combined to stimulate PBMC, IL-10 was only increased in the presence of *B*. *breve*, whereas exposing PBMC to *S*. *thermophilus* reduced the IL-10 level \[[@pone.0228531.ref046]\]. We also previously noted that monocyte cell line (U937), co-cultured with *S*. *thermophilus* 1342 stimulated production of high levels of IL-10 \[[@pone.0228531.ref001]\].

IL-18 is involved in the initiation of severe inflammatory responses, indicating the role of IL-18 in inflammatory and autoimmune disorders. Co-culture of PBMC with *S*. *thermophilus* 285 significantly downregulated IL-18 which indicates an anti-inflammatory role for *S*. *thermophilus* 285 bacteria. Likewise, a mixture of Lactobacilli species (*L*. *rhamnosus*, *L*. *paracasei*, and *L*. *plantarum*) was shown to supress the secretion of pro-inflammatory IL-18 gene by undifferentiated IPEC-1 intestinal porcine epithelial cell line \[[@pone.0228531.ref047]\], highlighting supportive role of lactobacilli probiotics in functioning against inflammation and suppression of immune response activities. However, other studies with other probiotics such as, *L*. *rhamnosus* E509, *L*. *rhamnosus* GG E522 (ATCC 53103), *L*. *bulgaricus* E585 and *S*. *pyogenes* serotype T1IH32030, increased IL-18 production by human PBMC \[[@pone.0228531.ref048]\]. Hence, different probiotic strains induce different cytokine profiles.

IL-2 is involved in signalling of immune responses and activates proliferation of lymphocytes. We note downregulation of IL-2 gene expression in PBMC after exposure to ST285. IL-23 known to activate Th17 cells was upregulated although IL-17, the key pro-inflammatory cytokine secreted by Th17 cells was not altered. Upregulation of IL-1α, IL-6, IL-10, and downregulation of IL-2, IL-18 and an absence of change in IL-17A (despite increase in IL-23α) designates ST285 to possess anti-inflammatory effects on human PBMC.

4.2 *S*. *thermophilus* 285 stimulates expression of cytokines involved in the defence against bacteria {#sec024}
-------------------------------------------------------------------------------------------------------

IFN-γ is an adaptive immunity cytokine secreted by Th1 cells in the defense response to microbes and viruses. IFN-γ is predominantly secreted by NK, NKT cells as part of the innate immune response, and by CD4 Th1 and CD8^+^ T cells of the adaptive immune response \[[@pone.0228531.ref049]\]. *S*. *thermophilus* 285 upregulated IFN-γ gene expression by human PBMCs. This is similar to studies of a combination of probiotic strains including *S*. *thermophilus*, *Lactobacillus*, *Bifidobacterium*, *Propionibacterium*, *E*. *coli* and *Leuconostoc* \[[@pone.0228531.ref050]\], where upregulation of IFN-γ mRNA expression by PBMC was noted \[[@pone.0228531.ref050]\]. Likewise, co-cultures of pooled PBMC with ST1275 also induced upregulation of IFN-γ \[[@pone.0228531.ref039]\]. We previously noted that monocyte cell line co-cultured with *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 or *S*. *thermophilus* 285 strains induced high levels of IFN-γ secretion \[[@pone.0228531.ref001]\]. In a study with Lactobacilli (*L*. *rhamnosus* E509, *L*. *rhamnosus* GG E522 (ATCC 53103) and *L*. *bulgaricus* E585), and streptococci (*S*. *pyogenesserotype* T1 IH32030), IFN-γ was produced by human PBMC \[[@pone.0228531.ref048]\].

IL-1β secretion by monocytes is involved in regulating immune and inflammatory responses to bacterial infections and injury, hence its role in innate immunity \[[@pone.0228531.ref051]\]. IL-1β is upregulated by *S*. *thermophilus* 285 co-cultured with PBMC, which is in accord with studies of PBMC co-cultured with mixed probiotics (*S*. *thermophilus*, *L*. *rhamnosus*, *L*. *casei*, *L*. *acidophilus*, *B*. *longum* and *B*. *bifidum*) \[[@pone.0228531.ref040]\]. We previously noted in monocyte cell line co-cultured with three different strains of *S*. *thermophilus*, only *S*. *thermophilus* 1342 stimulated production of high levels of IL-1β whereas, *S*. *thermophilus* 1275 and *S*. *thermophilus* 285 did not induce IL-1β cytokine \[[@pone.0228531.ref001]\]. A mixture of Lactobacilli strains (*L*. *rhamnosus*, *L*. *paracasei*, and *L*. *plantarum*) co-cultured with intestinal porcine epithelial cell line (IPEC-1) also upregulated IL-1β gene expression \[[@pone.0228531.ref047]\]. Similarly, the combination of *L*. *casei* Shirota, *L*. *rhamnosus* GG, *L*. *plantarum* NCIMB 8826 and *L*. *reuteri* NCIMB 11951, *B*. *bifidum* MF 20/5 and *B*. *longum* SP 07/3 co-cultured with PBMC, significantly augmented IL-1β production \[[@pone.0228531.ref041]\].

TNFα plays a key role in the defense against bacterial infections. It is a pro-inflammatory cytokine, which also supports recruitment and activation of T and B cells to promote an adaptive immune response. We previously demonstrated high levels of TNFα secretion by U937 monocyte cell line in the presence of *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 and *S*. *thermophilus* 285 \[[@pone.0228531.ref001]\]. Likewise, our current findings show that ST285 co-cultured with PBMC results in upregulation of TNFα. However, in a study using *B*. *breve* and ST together to stimulate PBMC, TNF-α secretion was inhibited \[[@pone.0228531.ref046]\]. In addition, a mixture of strains of probiotics (*L*. *casei* Shirota, *L*. *rhamnosus* GG, *L*. *plantarum* NCIMB 8826 and *L*. *reuteri* NCIMB 11951, *B*. *bifidum* MF 20/5 and *B*. *longum* SP 07/3) co-cultured with PBMC, significantly increased the production of TNFα \[[@pone.0228531.ref041]\]. In another study of human PBMCs exposed to different probiotics (*L*. *mesenteroides* ssp. cremoris PIA2 (DSM 18892) *S*. *pyogenes* serotype T1M1, *S*. *thermophilus* THS, *E*. *coli* (DH5α), *L*. *rhamnosus* Lc705 (DSM 7061), *L*. *lactis* ssp. cremoris ARH74 (DSM 18891), *L*. *rhamnosus* GG (ATCC 53103), *L*. *helveticus* Lb 161, *L*. *helveticus* 1129, *B*. *longum* 1/10, *B*. *breve* Bb99 (DSM 13692), *B*. *animalis* ssp. lactis Bb12, and *Propionibacterium* (*P*.) *freudenreichii* ssp. shermanii JS (DSM 7067)), all induced TNF-α mRNA expression \[[@pone.0228531.ref050]\]. Given that IFNγ, IL-1β and TNFα are upregulated by PBMC following co-culture with *S*. *thermophilus* 285 this suggests that *S*. *thermophilus* 285 induces powerful defense against invading pathogens and could be beneficial against virus infection and tumours.

The upregulation of IFNγ, IL-1β and TNFα coupled with a significant decrease in IFNγ receptor and IL-18 shows an antagonising effect of *S*. *thermophilus* 285 inflammatory responses and leading to an overall anti-inflammatory profile.

4.3. *S*. *thermophilus* 285 activates mRNA expression of CXCL8 and downregulates CCR5 and CXCL10 {#sec025}
-------------------------------------------------------------------------------------------------

IL-8, also known as CXCL8 is an important chemokine of the innate immune system, involved in the recrutiment of neutrophils and other granulocytes as the first line of defense \[[@pone.0228531.ref052]\]. *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 and *S*. *thermophilus* 285 were previously shown to activate U937 monocyte cell line to produce high levels of IL-8 \[[@pone.0228531.ref001]\]. The probiotic *L*. *paracasei* DG also increases expression of IL-8 to the human monocyte cell line, THP-1 \[[@pone.0228531.ref053]\]. Likewise, short chain fatty acids, produced by probiotic bacteria, also stimulate IL-8 secretion and mRNA levels to the human epithelial cell line HT-29 \[[@pone.0228531.ref011]\]. These studies are in accord to our current findings that *S*. *thermophilus* 285 upregulates CXCL8 production by human PBMC.

C-C chemokine receptor type 5 (CCR5, CD195) is involved in Th1 immune responses and its gene expression is downregulated by PBMC following *S*. *thermophilus* 285 co-culture. However, in mice prolonged feeding with VSL\#3 probiotic mixture shows significant gene upregulation of CCR5 \[[@pone.0228531.ref054]\]. Differences could be attributed to one probiotic strain applied and varying effects of the strain (*S*. *thermophilus*) used in current study versus a mixture of different strains and species used in mice VSL\#3 (*L*. *delbruekii Bulgaricus*, *L*. *casei*, *L*. *plantarum*, *L*. *acidophilus*, *B*. *breve*, *B*. *longum*, *B*. *infantis* and *S*. *thermophilus*).

CXC motif chemokine 10 (CXCL10), or IFN-γ-induced protein-10 (IP-10), is secreted by a number of cell types (endothelial cells, monocytes and fibroblasts). Few roles have been ascribed to CXCL10 including chemo-attraction of NK cells, monocytes/macrophages, T cells and DCs, favouring adhesion of T cells to endothelial cells, anti-cancer/tumour action, and preventing angiogenesis and bone marrow colony development. CXCL10 is downregulated in PBMC culture following *S*. *thermophilus* 285 exposure. Conversely, monocyte-derived DCs co-cultured with *B*. *breve* Bb99, *L*. *lactics* subsp. cremoris ARH74 and *S*. *thermophilus* THS increased expression of CXCL10 and *S*. *thermophilus* was the most efficient probiotic in the induction of CXCL10 \[[@pone.0228531.ref023]\]. Additionally, microarray results of the intestines of mice prolonged administrated with VSL\#3 probiotic mixture in healthy mice showed differential effects on intestinal immune parameters, including upregulation of CXC10 which contrasts with our findings \[[@pone.0228531.ref054]\]. The difference are most likely due to cell types, as well as bacterial strains in our study (PBMC co-cultured with *S*. *thermophilus* 285 bacteria) compared to using mouse cells exposed to three strains (*B*. *breve* Bb99, *L*. *lactics* subsp. cremoris ARH74 and *S*. *thermophilus* THS) in the other study. Also in the latter experiments, it is quite predictable to observe different results in mice intestine administered with VSL\#3 due to different cells involved in mice study in contrast to PBMC cell population.

In summary, increased expression of IL-8 on its own could singularly be indicative of inflammation, but in the context of all other upregulated anti-inflammatory cytokine and mediators found in this study, this may not be interpreted as an inflammatory effect. IL-8 upregulation might also be interpreted as requirement for the initial stimulatory effect of *S*. *thermophilus* 285 to switch on the immune responses by initiating innate immunity, which by the progress of immune response, expression of CCR5 (which in turn influences Th1 immune responses), as well as CXCL10 (induced by IFNγ) are reduced by *S*. *thermophilus* 285. This might be suggestive of modulation of immune responses by *S*. *thermophilus* 285 to keep the adaptive immune responses in check.

4.4. *S*. *thermophilus* 285 significantly upregulates mRNA expression level of colony stimulating factor {#sec026}
---------------------------------------------------------------------------------------------------------

CSF (GM-CSF) is secreted by machrophages, NK cells and T cells, enables cell proliferation and differentiation, stimulates the production of various immune cells, in particular it increases the production of machrophages which are important in fighting againts infections. CSF-2, is vastly increased (130 fold) by PBMC co-cultured with *S*. *thermophilus* 285 which is in alignment to our previous data whereby *S*. *thermophilus* 1275, *S*. *thermophilus* 1342 and *S*. *thermophilus* 285 induced U937 monocyte cell line to secrete high levels of GM-CSF with ST285 being the highest inducer \[[@pone.0228531.ref001]\]. Likewise, another study used RT^2^ Profiler PCR Arrays for mouse cytokines and chemokines to demonstrate that *L*. *rhamnosus* GR-1 (GR-1) induced high levels of granulocyte CSF (G-CSF) mRNA (60-fold) to bone marrow-derived mouse macrophages \[[@pone.0228531.ref055]\]. Likewise, PBMC co-cultured with *B*. *infantis* 52486 significantly increases GM-CSF \[[@pone.0228531.ref056]\].

GM-CSF is generally accepted as an inflammatory cytokine, its inflammatory activity is primarily associated with its role as granulocytes and macrophages growth and differentiation factor. GM-CSF-mediated inflammation has also been associated with certain types of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. However, in many instances GM-CSF plays anti-inflammatory/regulatory roles; GM-CSF can modulate differentiation of DC to render them into tolerogenic DCs, which, can stimulate anti-inflammatory Treg cells \[[@pone.0228531.ref057]\]. In addition, either of pro-inflammatory or regulatory effects of GM-CSF appears to be dependent on the amount of CSF and the presence of other relevant cytokines in the context of an immune response. There is also evidence that G-CSF induces expansion of IL-10-producing cells \[[@pone.0228531.ref058]\]. Our results show very high overexpression of CSF, which might be suggestive of anti-inflammatory effect of *S*. *thermophilus* 285 on PBMC.

4.5. *S*. *thermophilus* 285 downregulates mRNA expression levels of toll-like receptors {#sec027}
----------------------------------------------------------------------------------------

Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious bacteria and mediate the production of cytokines necessary for the development of effective immunity \[[@pone.0228531.ref059]\]. TLRs recognize pathogens and activate the innate immune responses. TLR-1, TLR-2, TLR-4 and TLR-8 are part of the innate immune response and are involved in defense against bacteria. Co-culturing *S*. *thermophilus* 285 with human PBMC downregulated the expression of TLR. Similarly, *E*. *coli* K88 and mycotoxin zearalenone (ZEA) infection of IPEC-1 epithelial cell line was protected in the presence of mixed Lactobacillus strains (*L*. *acidofilus* ID11692, *L*. *plantarum* ID1253 and *L*. *paracasei* ID13239) by downregulating TLR-1, TLR-2 and TLR-4 gene expression \[[@pone.0228531.ref060]\].

TLRs are critical in bacterial recognition and host defence, such as lipo-teichionic acid (LTA) and lipo-polysaccharide (LPS) from Gram-positive and Gram-negative bacteria respectively \[[@pone.0228531.ref061], [@pone.0228531.ref062]\]. Activation of some of these molecules and mediators like TLR (especially TLR-2 and TLR-4) arbitrates to pro-inflammatory actions and further defensive functions of innate immunity \[[@pone.0228531.ref063]--[@pone.0228531.ref065]\]. The TLR-2 and TLR-4 activation and expression by LPS (pathogens) is known as one of the most important mechanisms by which the immune system controls reactions to bacteria in particular in the activation phase, therefore, over-expression of TLR-2 and TLR-4 during any bacterial infection could cause an elevated inflammatory response in the body. While early activation of TLRs expression is reported in response to bacterial LPS from pathogenic *Salmonella typhimurium* \[[@pone.0228531.ref061]\] as well as *E*. *coli* infection in bovine intestinal epithelial cells \[[@pone.0228531.ref066]\], our results show tolerance as a result of co-culturing PBMC with *S*. *thermophilus* 285 by down regulation of TLRs genes.

Downregulated mRNA expression of TLRs genes, specifically TLR-1, TLR-2, TLR-4 and TLR-8 indicates anti-inflammatory characteristics for *S*. *thermophilus* 285. Given that TLR-1, TLR-2, TLR-4 and TLR-8 are members of the innate immune response and play key roles in the defense against bacteria, downregulation of TLRs could be suggestive of a protective mechanism to keep *S*. *thermophilus* 285 safe by tolerance towards *S*. *thermophilus* 285. Perhaps designing experiments that allow different incubation period, as well as adding pathogenic bacteria to the co-cultured *S*. *thermophilus* 285-PBMC can help to illustrate if lesser co-culture time and/or presence of pathogens can result in a shift towards upregulation of TLRs instead.

4.6. *S*. *thermophilus* 285 downregulates cell surface markers CD14, CD40, CD86 {#sec028}
--------------------------------------------------------------------------------

CD14, CD40 CD86 are expressed on the cell surface of monocytes, macrophages and DC. CD14 is expressed on the surface of monocytes and primarily binds to bacterial constituents \[[@pone.0228531.ref067]--[@pone.0228531.ref069]\]. We previously showed that U937 monocyte cell line exposed to *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 or *S*. *thermophilus* 285 enhanced expression of CD14 after 24 and 48 hrs, and *S*. *thermophilus* 285 was the most potent at 48 hrs \[[@pone.0228531.ref001]\]. However, in bulk PBMC cultures, CD14 expression was significantly downregulated in the presence of *S*. *thermophilus* 285, which is in accordance with downregulation of TRLs in particular TRL-4. In other studies, the combination of 3 probiotics (*L*. *acidophilus*, *L*. *delbrueckii* ssp. *bulgaricus* and *B*. *bifidum*) stimulated increased expression of cell surface markers, CD14, CD80 and MHC class II \[[@pone.0228531.ref001]\]. *E*. *coli* Nissle 1917, widely used as a probiotic for the treatment of inflammatory bowel disorders, expresses a K5 capsule important in *E*. *coli* mediating interactions with intestinal epithelial cells and chemokine expression. *E*. *coli* Nissle 1917 has been shown to induce mRNA expression of CD14 by intestinal Caco-2 cells \[[@pone.0228531.ref070]\].

CD40 is a costimulatory protein on antigen presenting cells and is essential for their activation. CD40 is a key mediator in a wide range of inflammatory and immune responses and its gene expression was downregulated by PBMC in the presence of *S*. *thermophilus* 285. In previous experiments with U937 monocyte cell line, co-culture with *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 or *S*. *thermophilus* 285, resulted in small increase in CD40 \[[@pone.0228531.ref001]\].

CD86 (B7-2) is expressed on APCs and delivers co-stimulatory signals required for the activation and survival of T cells. CD86 plays the role of the ligand for T cells external CD28, and CTLA-4 (CD28) in regulation and cell to cell dis-association. CD86 acts in conjunction with CD80 to prime Th cells, delivering opposing functions on Treg cells through CTLA-4 and T cell surface CD28 protein. Expression of CD86 by PBMC is downregulated significantly, suggesting an anti-inflammatory profile following exposure to *S*. *thermophilus* 285. *S*. *thermophilus* bacteria promote CD86 expression required for T cell activation and the maintenance of immune responses, CD86 downregulation by *S*. *thermophilus* 285 suggests a regulating and damping effect of *S*. *thermophilus* 285 on PBMC, being interpreted as immunomodulation of adaptive immunity \[[@pone.0228531.ref071]\]. We previously noted using U937 monocyte cell line in the presence of *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 and *S*. *thermophilus* ST285 increased expression of CD86 \[[@pone.0228531.ref001]\]. Similarly, *L*. *plantarum* WCFS1 and *L*. *fermentum* GR1485 upregulate CD86 on monocytes, conversely, *L*. *rhamnosus* and *L*. *delbruekii* reduced its expression \[[@pone.0228531.ref072]\].

Additionally, monocytes isolated from PBMC and differentiated into immature DCs by GM-CSF and IL-4, and co-cultured with *B*. *breve* Bb99, *L*. *lactis* subsp. cremoris ARH74 and *S*. *thermophilus* THS also increase CD86 expression \[[@pone.0228531.ref023]\]. Another study used bone marrow-derived DCs from DQ8-transgenic mice and co-culture with *L*. *plantarum* and *L*. *paracasei* and *B*. *lactis* increases CD86 differentially with the highest CD86 being noted in co-administration of *L*. *plantarum* and *L*. *paracasei* \[[@pone.0228531.ref073]\]. The contrast between these studies to the findings herein could be due to the differences in the nature of studies; we co-cultured PBMC with *S*. *thermophilus* 285 bacteria only and the other studies used mouse bone marrow-derived DCs co-cultured with three different probiotics leading to predictable differences.

Given the downregulation of cell surface markers and their roles in immunity, CD14 (involved in innate immunity), CD40 (involved in innate immunity), and CD86 (T cell activation), following *S*. *thermophilus* 285 co-culture is suggestive of an anti-inflammatory anti-activation profile for *S*. *thermophilus* 285. In addition, as all these cell surface markers are interlinked with defence against bacteria either through innate or adaptive immune responses, downregulation of these markers could be suggestive of *S*. *thermophilus* 285 initiating self-tolerance via regulating immune responses, which in turn modulates the immune responses too.

4.7. *S*. *thermophilus* 285 differentially downregulates mRNA expression level of other innate and adaptive immune response markers and chemokines {#sec029}
---------------------------------------------------------------------------------------------------------------------------------------------------

Complement component 3 (C3) is associated with complement cascades in immune responses by enhancing antibody function, phagocytosis and stimulation of inflammation \[[@pone.0228531.ref074]--[@pone.0228531.ref076]\]. GATA3 transcriptome is also important in both humoral immunity and inflammatory responses. Downregulation of C3 gene expression and significant reduced expression of GATA3 transcriptome by PBMC co-cultured with *S*. *thermophilus* 285 in noted. Similarly, lipoteichoic acid (p-LTA) extracted from *L*. *plantarum* K8 inhibits C3 mRNA *in vitro* and *in vivo*. In human clinical studies, blocking GATA3 is able to control allergy responses, inflammatory diseases and asthma \[[@pone.0228531.ref077]\]. C3 and GATA3 downregulation suggests that *S*. *thermophilus* 285 is able to lower inflammation (C3), as well as being a viable candidate for further pre-clinical and clinical studies for the management of such diseases.

Interferon regulatory factor (IRF) 7, integrin alpha M (ITGAM), Lysozyme (LYZ) and NALP3 are other innate immune response factors. IRF7, a member of IRF family and present on monocytes, macrophages, granulocytes, and NK cells, and expressed predominantly in macrophages (a component of the inflammasome) \[[@pone.0228531.ref078]\]. IRF7 plays a role in the transcriptional activation of virus-inducible cellular genes, including the type I interferon genes. ITGAM is involved in a number of inflammatory responses (i.e. cell-mediated cytotoxicity, phagocytosis, and chemotaxis). LYZ acts as an antimicrobial enzyme present in neutrophils and macrophages. IRF7 gene regulation decreased considerably along with ITGAM gene expression, which is downregulated when PBMC are co-cultured with *S*. *thermophilus* 285. NALP3 and LYZ are downregulated markedly in co-culture of PBMC with *S*. *thermophilus* 285. However, in a previous study, we showed significant upregulation of CD11b (ITGAM) by monocytic U937 cells when co-cultured with *S*. *thermophilus* 1342, *S*. *thermophilus* 1275 and *S*. *thermophilus* 285 bacteria \[[@pone.0228531.ref001]\]. *S*. *thermophilus* 285-induced downregulation of IRF7, ITGAM, NALP3 and LYZ in PBMC, suggestive of an anti-inflammatory effect of *S*. *thermophilus* 285 on PBMC as well.

Non-receptor tyrosine-protein kinase (TYK2) is an enzyme \[[@pone.0228531.ref007]\] that contributes to adaptive immune responses due to its implication in IFNα, IL-6, IL-10 and IL-12 signaling, also involved in transducing signals of IL-6, IL-10 and IL-23. TYK2 gene expression is significantly downregulated in PBMC co-cultured with *S*. *thermophilus* 285, supporting an anti-inflammatory profile for *S*. *thermophilus* 285. In addition, myeloperoxidase (MPO), an enzyme abundantly expressed by neutrophils and promotes inflammation, is also involved in autoimmune disorders (multiple sclerosis, rheumatoid arthritis) \[[@pone.0228531.ref079], [@pone.0228531.ref080]\]. A decreased expression of MPO has been suggested to manage these autoimmune disorders by decreasing the inflammatory state. *S*. *thermophilus* 285 co-cultured with PBMC decreased the expression of MPO, suggestive of an anti-inflammatory benefit of *S*. *thermophilus* 285.

IFNAR1 is a type I membrane protein which is a receptor for IFNα and IFNβ involved in defence against viruses. IFNAR1 signaling is associated with pro-inflammatory cytokine production \[[@pone.0228531.ref081]\]. In fact, IFNAR1 knockout mice show decreased pro-inflammatory cytokiens and chemokines \[[@pone.0228531.ref081]\]. IFNAR1 is significantly downregulated by PBMC following co-culture with ST285, supporting an anti-inflammatory role of *S*. *thermophilus* 285. In addition, SLC11A1 involved in T cell activation, is involved in inflammatory disorders such as autoimmune type 1 diabetes \[[@pone.0228531.ref082], [@pone.0228531.ref083]\], is downregulated by PBMC in the presence of *S*. *thermophilus* 285. Furthermore, the Beta-actin (ACTB) which stimulates eNOS and increase nitric oxide (NO) \[[@pone.0228531.ref084]\] involved in immunity and inflammation \[[@pone.0228531.ref085]\], is downregulated by PBMC following co-culture with *S*. *thermophilus* 285.

We determined the immune modulatory effects of *S*. *thermophilus* 285 to human PBMC and show that it has an array of anti-inflammatory immune-modulatory properties. *S*. *thermophilus* 285 decreases mRNA expression IL-18, IFNγR1, CCR5, CXCL10, TLR-1, TLR-2, TLR-4, TLR-8, CD14, CD40, CD86, C3, GATA3, ITGAM, IRF7, NLP3, LYZ, TYK2, IFNR1, and upregulates IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-23, IFNγ, TNFα, CSF-2. No changes to mRNA expression are noted with IFNA1, IFNB1, IL-4, IL-5, IL-13, CCL2, CCL5, CCL8, CCR4, CCR8, CXCR3, TLR-3, TLR-5, TLR-6, TLR-9, CD4, CD80, FOXP3, STAT3, CD40LG, HLA-A, HLA-E, RORC. The data demonstrates a predominant anti-inflammatory profile exhibited by *S*. *thermophilus* 285, and further work is required to determine its effects in inflammatory disease models *in vitro* and *in vivo*, such as multiple sclerosis, inflammatory bowel disease and allergies. Future investigations using RNA-Seq and Western blots are some of the next logical steps to confirm and further investigate these results.

5. Conclusion {#sec030}
=============

Probiotics are beneficial microorganism with immunomodulatory properties, which aid the maintenance of a healthy immune system. *S*. *thermophilus* is often used in fermented dairy products such as cheeses and yogurts and is believed to potentially have health benefits. We determined the immune modulatory effects of *S*. *thermophilus* 285 to human peripheral blood mononuclear cells and show that it has an array of anti-inflammatory immune-modulatory properties. *S*. *thermophilus* 285 decreases mRNA expression IL-18, IFN receptor, CCR5, CXCL10, TLR-1, TLR-2, TLR-4, TLR-8, CD14, CD40, CD86, C3, GATA3, ITGAM, IRF7, NLP3, LYZ, TYK2, IFNR1, and upregulates IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-23, IFN-γ, TNF-α, CSF-2. No changes to mRNA expression were noted with IFNA1, IFNB1, IL-4, IL-5, IL-13, CCL2, CCL5, CCL8, CCR4, CCR8, CXCR3, TLR-3, TLR-5, TLR-6, TLR-9, CD4, CD80, FOXP3, STAT3, CD40LG, HLA-A, HLA-E, RORC.

Supporting information {#sec031}
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###### List of the innate or adaptive genes and housekeeping genes; their symbols, full name and description that are investigated in in this study.

(DOCX)
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Click here for additional data file.

###### Presentation of data as a heatmap of average gene/RNA expressions of PBMC (n = 3) co-cultured with *S*. *thermophilus* ST285, compared to control.

Green represents down regulated genes to red represents upregulated genes.
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Click here for additional data file.
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4\. The presentation of the data needs to be improved. Particularly, the heat map in fig 1 is difficult to read. Usually, heat map data are presented using hierarchical clustering, with the genes on 1 axis and donors on another axis, to clearly display the differences between stimulated and unstimulated. Next, the author did one-way ANOVA analysis for all the figures, I assume its between different genes displayed in each panel. This is unnecessary since which genes goes into which panel is arbitrary. Instead, since each donor have a un-stimulated controls, the author should use wilcoxon-matched pairs signed rank test for each respective gene. Lastly, while the mean value of the unstimulated controls will be 1, they should still be plotted in to display the variation between them.

Reviewer \#2: You had a conclusion as a \'\'upregulation of IL-1 alpha, IL-6, IL 10, and downregulation of IL-2, IL-18 and an absence of change in IL-17A (despite increase in IL-23 alpha) designates ST285 to possess anti inflammatory effects on human PBMC\'\'.

Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine.Interleukin (IL)-6 is produced at the site of inflammation and plays a key role in the acute phase response as defined by a variety of clinical and biological features such as the production of acute phase proteins.

In general, Interleukin 1 alpha is responsible for the production of inflammation, as well as the promotion of fever and sepsis. We can say both of IL-1 and IL-6 have inflamatuarty affect. So that, It should be explained how you interpret the increase of IL-1 alpha and IL-6 syntheses as anti-inflammatory effect.

When writing bacterial names should be paid attention to Nomenclature of Microorganisms. Binary names, consisting of a generic name and a specific epithet (e.g., Escherichia coli), must be used for all microorganisms. Names of genus level may be used alone, but specific and subspecific epithets may not. A specific epithet must be preceded by a generic name, written out in full the first time it is used in a paper. Thereafter, the generic name should be abbreviated to the initial capital letter (e.g., E. coli), provided there can be no confusion with other genera used in the paper.

Reviewer \#3: 1- Authors gave information about PBMC in the section of Materials and Methods which can be presented in the introduction section.

2- Authors did not write the number of the collected whole blood samples used in this study in the section of Materials and methods but they wrote it in the result section. (please write it in the materials and Methods section).

3- It is preferable to list the genes and housekeeping genes tested in this study (as supplementary file), their reaction conditions and their role as innate or adaptive to be helpful for any researcher in his study.

Reviewer \#4: Dargahi et al. discusses the possible effects of Streptococcus thermophilus on innate and adaptive immune response using in vitro (ex vivo) PBMCs. The objective of this study according to the authors was to understand Streptococcus thermophilus anti-inflammatory and modulatory properties. Streptococcus thermophilus is used as probiotic and affects gut microbiome.

The manuscript is clear and well-written with detailed materials and methods section. However, I believe the authors could have consolidated the figures into 3 or 4 figures as the results section was lengthy describing just a single experiment.

There are drawbacks of this study, first of all, the whole study is based on a single experiment of isolation of PBMCs from buffy coats from blood bank and performing an expression mini-array (qPCR profiling array of 84 genes). To start with, if that\'s the only experiment done, authors should have tried to get better quality RNA by storing the lysed PBMCs (treated and untreated) in the lysis buffer of the provided manufacturer. If that was done, RNA quality would have been much better than going to RIN values of 7.5, they could have easily reached 10 with minimum of 8.5 (high quality RNA). Another thing is that other experiments could have been done to support the expression analysis data and take it a step further.

The authors drew too many conclusions from just qPCR profiling of the treated and untreated PBMCs. Additional supporting experiments should have been done.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Teck-Hui Teo

Reviewer \#2: No

Reviewer \#3: Yes: Rehab Mahmoud Abd El-Baky

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

24 Nov 2019

Reviewers\' comments:

Reviewer\'s Responses to Questions

Reviewer \#1: The manuscripts presented by Dargahi et al presented data of only mRNA expression in the PMBC of donors to conclude the immune regulation by Streptococcus thermphilus. While the premise to study Streptococcus thermphilus is interesting because of their applications as probiotics, there are several major flaws in the experimental model used that must be addressed.

Major comments:

1\. The relevance of the experimental model used needs to be justify. The authors used PBMC co-culture with ST285 as the primary system to explain the immune regulation properties of the bacteria. Streptococcus thermphilus is a probiotic, and they generally exist within the mucous layer of the gut and do not cross over to meet immune cells in the blood where the PBMC are harvested from. Importantly, there are a wide array of studies demonstrating that the immune cells in the gut differ from the PBMC both in terms of activation status and proportion of different subsets. The authors need to justify the use of PBMCs and limit conclusion to immune subsets which are comparable between the gut and the blood.

Answer: The Reviewer \# 1 correctly refers to the natural habitat of the probiotics/ microflora inside human body, and the difference between circulating immune cells and the one in the gut. However, PBMC are some of the very common models which are commonly used to examine human immune response to different stimuli including those from bacteria and probiotics. Numerous cell types are involved in maintenance of the intestinal tissue. However, the main players are cells of the epithelial lining and the immune system. Human PBMCs are used to investigate the effect of probiotics, food bioactives and many different stimuli on various immune cells because these cells are easily isolated from blood of healthy donors or buffy coats (buffy coats are leukocyte concentrates; a by-product from anti-coagulated whole blood by Blood Banks in the manufacturing of red blood cell and thrombocyte concentrates). Even though PBMCs have a different composition, phenotype and activation status than cells found in intestinal tissue, utilising PBMC has been known as a valuable test system for investigation of immune modulatory effects of probiotic bacteria and many other compounds. For this reason using PBMC has been used in the current study as well as in many studies to determine immune-modulatory responses. In addition, there is an interaction between PBMCs and intestinal cells, hence PBMC can influence intestinal cells. In 2013 a paper published in PLOS One showed that there is interaction of PBMC with intestinal epithelial cells and that the probiotic Lactobacillus casei was able to modulate cytokine responses to human PBMC making them immunosuppressive (Tittanen, M et al., 2013) similar to the findings with ST285 in our studies. However, we have assessed an entire spectrum of cytokines and genes involved in the innate and adaptive immune response and determined the immune modulatory effects of ST285 to PBMC.

2\. In this co-culture system, the control used is without the bacteria. It would be important to include a unrelated bacteria strain such as E.coli to emphasize the specificity of the response induced by ST285.

Answer: As reviewer accurately stated many studies use E.coli as positive control. E.coli has been proved over and over to trigger pro-inflammatory responses. In mRNA and gene expression studies, the tested/treated samples are always compared against a control which could be either positive control/E.coli or an untreated control samples. Comparing expression of genes against E.coli would provide a much larger up or down regulation of the changed genes, which could have led to an exaggerated up or down regulation of altered genes. Probiotic treated PBMC samples were compared against untreated ones which are the most common practice in PCR and specifically gene arrays (REF). In addition, in our previous publication, (Narges et al, Journal of Functional Foods 2018) we showed that LPS (an extract from E. coli) induced a pro-inflammatory profile to monocyte cell line. Here we demonstrate the effects of the probiotic bacteria ST285 effects on PBMC which induces a predominant anti-inflammatory profile.

3\. The entire paper relied solely on gross gene expression data from total PBMC. This lacks the specificity to understand the impact on specific cell type in the fraction because most cytokines could be produced by more than 1 cell type. In addition, there are no protein expression data to back up the conclusion. I would propose doing intracellular staining of cytokines in specific subsets through flowcytometry in the PBMC on the core cytokines identified from the gene expression study.

Answer: The reviewer raises a valid point. In fact, we previously determined 12 individual cell surface markers through flowcytometry and also studied secretion of 9 major cytokine and chemokines via bioplex (Dargahi et al, 2018). In these studies, the same probiotic (ST285) was used as in the current study. However, the aim of the current study was to determine a wide range of genes that covers most of cell surface markers, cytokine and chemokines to provide a bigger picture of immune modulatory properties of ST285. We have added a comment in the discussion to make our previous findings clearer.

4\. The presentation of the data needs to be improved. Particularly, the heat map in fig 1 is difficult to read. Usually, heat map data are presented using hierarchical clustering, with the genes on 1 axis and donors on another axis, to clearly display the differences between stimulated and unstimulated. Next, the author did one-way ANOVA analysis for all the figures, I assume its between different genes displayed in each panel. This is unnecessary since which genes goes into which panel is arbitrary. Instead, since each donor have a un-stimulated controls, the author should use wilcoxon-matched pairs signed rank test for each respective gene. Lastly, while the mean value of the unstimulated controls will be 1, they should still be plotted in to display the variation between them.

Answer: The data presentation has now been improved for a better read of the heat map in fig S1. Also hierarchical clusters (fig1B) have now been added for a better and clearer presentation of obtained data.

The statistical analysis has been conducted using Qiagen web-based software (Qiagen RT2 profiler data analysis webportal) which is strongly recommended when using gene arrays. Then calculated the fold changes and analyzed data manually to compare results. Qiagen webportal uses internal controls that includes PCR array reproducibility control, RT efficiency control and genomic DNA contamination control, and ensures all arrays successfully passed all of these check point controls. Normalization of the raw data was performed using the included housekeeping genes (HKG) panel. In this system, means of 3 tested samples were compared against untreated.

The fold changes of unstimulated controls were calculated and considered as background expression, therefore those values have been deducted from the obtained gene expressions for tested samples to present real fold changes minus background (untreated controls). ).

Wilcoxon is more appropriate for n ≥ 5 analysis and ANOVA is commonly used for this analysis. The confusion had arisen due to a lack of clarity in the methodology (it wasn't conducted between genes, but between treatment vs control), which has been amended for clarity.

Reviewer \#2: You had a conclusion as a \'\'upregulation of IL-1 alpha, IL-6, IL 10, and downregulation of IL-2, IL-18 and an absence of change in IL-17A (despite increase in IL-23 alpha) designates ST285 to possess anti inflammatory effects on human PBMC\'\'.

Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. Interleukin (IL)-6 is produced at the site of inflammation and plays a key role in the acute phase response as defined by a variety of clinical and biological features such as the production of acute phase proteins.

In general, Interleukin 1 alpha is responsible for the production of inflammation, as well as the promotion of fever and sepsis. We can say both of IL-1 and IL-6 have inflamatuarty affect. So that, It should be explained how you interpret the increase of IL-1 alpha and IL-6 syntheses as anti-inflammatory effect.

Answer: Reviewer \#2 appropriately refers to the functions of IL-1a and IL-6. IL-1α (and IL-1β) has strong pro-inflammatory effect, however, it perform its roles via IL-1Ra (IL-1 receptor antagonist). The conclusion about the inti-inflammatory profile for ST285 is based on the overall effect of ST285 on PBMC. Despite the fact that the expression of IL-1a gene is increased, there is no increase in the expression for IL-1R which is required for the pro-inflammatory immune responses mediated by IL-1a and this may cause substantial reduction in reactions associated with IL-1a. Regarding IL-6, there has been a constant shifting in the pro- and anti-inflammatory dynamics and the equilibrium between them that leads to some controversy in research findings. IL-6 is one of the cytokines with both pro- and anti-inflammatory effects, whether IL-6 wears a pro- and anti-inflammatory mask all depends on the bio-environment. Once more, conclusion in this manuscript is driven based on the overall effect of ST285 bacteria and the results that support an anti-inflammatory environment caused by the bacterial stimulation. We have altered the discussion to include this reasoning for better clarity to the readers

When writing bacterial names should be paid attention to Nomenclature of Microorganisms. Binary names, consisting of a generic name and a specific epithet (e.g., Escherichia coli), must be used for all microorganisms. Names of genus level may be used alone, but specific and subspecific epithets may not. A specific epithet must be preceded by a generic name, written out in full the first time it is used in a paper. Thereafter, the generic name should be abbreviated to the initial capital letter (e.g., E. coli), provided there can be no confusion with other genera used in the paper.

Answer: Although the binary nomenclature is the accurate and accepted way to state bacterial cultures, in some publications after the second time of writing abbreviated to the initial capital letter (e.g., E. coli), abbreviations are often used to save space and avoid repetition of names which are long. However, all the 2 latter abbreviations are replaced with the appropriate binary nomenclature as recommended by Reviewer \#2.

Reviewer \#3:

1- Authors gave information about PBMC in the section of Materials and Methods which can be presented in the introduction section.

Answer: This information was removed from the material and methodology section and added to the introduction.

2- Authors did not write the number of the collected whole blood samples used in this study in the section of Materials and methods but they wrote it in the result section. (please write it in the materials and Methods section).

Answer: The number of collected blood samples has now been added to the materials and Methods section

3- It is preferable to list the genes and housekeeping genes tested in this study (as supplementary file), their reaction conditions and their role as innate or adaptive to be helpful for any researcher in his study.

Answer: A list of the genes and housekeeping genes tested in this study has been added as a supplementary file, and their reaction conditions and their role in innate or adaptive immune responses has been briefly added as well (Table 1).

Reviewer \#4: Dargahi et al. discusses the possible effects of Streptococcus thermophilus on innate and adaptive immune response using in vitro (ex vivo) PBMCs. The objective of this study according to the authors was to understand Streptococcus thermophilus anti-inflammatory and modulatory properties. Streptococcus thermophilus is used as probiotic and affects gut microbiome.

The manuscript is clear and well-written with detailed materials and methods section. However, I believe the authors could have consolidated the figures into 3 or 4 figures as the results section was lengthy describing just a single experiment.

Answer: the cytokine, chemokines and surface markers have been categorized and grouped based on their role in the immune system for a more cohesive description and better understanding of readers of non-immunological background. Due to reasons mentioned for systemic classification of the genes, combining 8 figures into 3-4 mixes up the results and discussion. Ideally it is best to keep the results and figures as they are.

There are drawbacks of this study, first of all, the whole study is based on a single experiment of isolation of PBMCs from buffy coats from blood bank and performing an expression mini-array (qPCR profiling array of 84 genes). To start with, if that\'s the only experiment done, authors should have tried to get better quality RNA by storing the lysed PBMCs (treated and untreated) in the lysis buffer of the provided manufacturer. If that was done, RNA quality would have been much better than going to RIN values of 7.5, they could have easily reached 10 with minimum of 8.5 (high quality RNA).

Answer: Human PBMC consist of sensitive cell populations, and, as blood samples are being processed for the purpose of PBMC isolation, they go through multiple centrifugation and washes and the process affects the cells. For this reason, and because of some level of ribonucleases produced by some of these cells, it is hard to obtain RNA with RIN 10. Although using cell lines and tissues obtaining RIN of 9.5-10 is much more feasible and we showed this in our previous publications. Any RNA of RIN 7 and above has been considered acceptable and enough high RNA quality. Several blood samples were used for PBMC isolation, treatment and extraction of RNA and only RNA samples with the highest RIN numbers (all above 8) were included for PCR. We have made this clearer in the material and methodology and results sections.

Another thing is that other experiments could have been done to support the expression analysis data and take it a step further.

The authors drew too many conclusions from just qPCR profiling of the treated and untreated PBMCs. Additional supporting experiments should have been done.

Answer: In our previous publications we showed immune modulatory effects using secreted cytokines using bioplex assays, and, flow cytometry of immune cell surface marker changes, in particular, monocyte cells. In the current study, we aimed to get a more comprehensive overview of the data, by undertaking an in depth gene array analysis of the effects of probiotics to human PBMC. We have altered the discussion to make this clearer to the readers. In this regard, we are currently determining the effects of probiotics using RNAseq and protein expression by western blot, and that data will be part of another publication.

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Answer: Yes we agree
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Narges Dargahi

Victoria University, Australia
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Dear Dr. Dargahi,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Hossam M Ashour

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The authors have satisfactorily responded to all my questions and made the necessary changes to the manuscript.

Reviewer \#3: (No Response)

Reviewer \#4: Most of my comments have been addressed. However, I still think the supporting data is not enough for the conclusions, so it is up to the editor to see what fits publication in PLoS ONE.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Ali Acar

Reviewer \#3: Yes: Rehab Mahmoud Abd El-Baky

Reviewer \#4: No
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